NASDAQ · IMRX
Immuneering Corporation
Healthcare · Biotechnology
$3.67▲ 5.01% ($0.18)at close
After hours$3.68▲ 0.41%7:30 PM ET
Market cap
$237.36M
P/E
N/M
EPS (TTM)
-$1.03
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need current revenue and shares outstanding to build the revenue-driven FCFF model.
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Data notes
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $3.67 · Price Nov 3, 4:50 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 43.9% over the last year.
What the market seems to be pricing
The stock has moved lower with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or free cash flow over the next period would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Mar 5, 2027
Q4 FY26 · EPS est -$0.37 · Revenue est —
Q3 FY26
Reported Oct 29, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.37
Estimate
-$0.31
Year over year
n/m
Vs prior quarter
n/m
2 beats · 2 misses in the last 4 quarters
Institutional Sentiment
Immuneering Corporation · IMRX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.